Barzilai Medical Center

Phoenix Holdings Publishes Financial Statements for Q4 and 2023

Retrieved on: 
Wednesday, March 27, 2024
Professional Services, Business, Insurance, Finance, Asset Management, Consulting, Banking, Friends, The Phoenix Companies, Growth, Memory, Share repurchase, Corporation, Policy, TLV, Acquisition, Tel Aviv Stock Exchange, Life, Credit, Solvency, Asset management, Report, SME, Analyst, Safety, Barzilai Medical Center, P&C, Holding, Collection, Pain, Rehabilitation, Mobile phone

Phoenix Holdings Ltd., a leading Israel-based financial, insurance, and investment group (TLV:PHOE) (“Phoenix,” the “Group,” or the “Company”), today reported its results for the fourth quarter of 2023 and calendar year 2023.

Key Points: 
  • Phoenix Holdings Ltd., a leading Israel-based financial, insurance, and investment group (TLV:PHOE) (“Phoenix,” the “Group,” or the “Company”), today reported its results for the fourth quarter of 2023 and calendar year 2023.
  • Phoenix is financially resilient with high levels of liquidity and a high Solvency II ratio for Phoenix Insurance, which reached 209% with transitional measures as of September 30, 2023.
  • Comprehensive income before tax in 2023 amounted to NIS 241 million, compared to NIS 235 million in 2022.
  • Comprehensive income before tax in 2023 amounted to NIS 307 million, compared to NIS 300 million in 2022.

Phoenix Holdings Publishes Financial Results for Q3 2023, with Continued Improvement in Core Income

Retrieved on: 
Thursday, November 30, 2023
Professional Services, Business, Insurance, Finance, Asset Management, Consulting, Banking, The Phoenix Companies, Courage, ROE, Tel Aviv Stock Exchange, Hope, Organization, Analyst, Corporation, Barzilai Medical Center, Report, TLV, Person, Total, Memory, Growth, Holding, P&C, Tourism, Real estate, Beauty salon, Management, Cryptocurrency, Phoenix, Psagot

Phoenix Holdings Ltd., a leading Israel-based financial, insurance, and investment group (TLV:PHOE) (“Phoenix,” the “Group,” or the “Company”), today reported its results for the third quarter of 2023.

Key Points: 
  • Phoenix Holdings Ltd., a leading Israel-based financial, insurance, and investment group (TLV:PHOE) (“Phoenix,” the “Group,” or the “Company”), today reported its results for the third quarter of 2023.
  • Phoenix made direct donations and facilitated donations from organizations and people around the world for immediate and urgent needs.
  • The results for the third quarter of 2023 reflect the continued improvement in core income across the Group’s activities and the continued execution of our growth strategy in the insurance, asset management, distribution, and credit businesses.
  • The comprehensive income before tax for the third quarter of 2023 amounted to NIS 22 million, compared to a comprehensive income of NIS 24 million before tax in the third quarter of 2022.

Cross River Accelerates Plan to Upgrade Ambulance Bays in Israel through its Bays of Life Initiative

Retrieved on: 
Thursday, October 19, 2023
Other Health, Law Enforcement, Emergency Services, Finance, Fintech, Banking, Managed Care, Professional Services, General Health, Philanthropy, Hospitals, Public Policy, Government, Fund Raising, Foundation, Other Philanthropy, Health, National Association Medical Staff Services, Cross River Bank, Riverbank, Bay, Courage, Face, Organization, Trauma, Friends, Barzilai Medical Center, Organic, Hospital, Sympathy, Patient, Empathy, Mental health, Nursing, Hatzalah

Cross River Bank (“Cross River”), a technology infrastructure provider that offers embedded financial solutions, and Foundation@ Cross River, its philanthropic arm, today announced its Bays of Life initiative, an effort to double down on its long-standing mission to upgrade ambulance bays in Israel.

Key Points: 
  • Cross River Bank (“Cross River”), a technology infrastructure provider that offers embedded financial solutions, and Foundation@ Cross River, its philanthropic arm, today announced its Bays of Life initiative, an effort to double down on its long-standing mission to upgrade ambulance bays in Israel.
  • The initial Bays of Life contribution will go to Barzilai Medical Center in Ashkelon, Israel.
  • "We are proud and honored to play a small part in the Hospital’s life-saving mission through our Bays of Life project.
  • Companies, foundations or other organizations who wish to join Cross River’s Bays of Life initiative, please reach out to [email protected] .

Jefferies Clients, Shareholders and Employees Donate $8.6 Million to Provide Humanitarian Aid in Israel

Retrieved on: 
Wednesday, October 11, 2023
Banking, Professional Services, Finance, COVID-19, Jefferies, Soroka Medical Center, Kaplan Medical Center, Sheba Medical Center, International Red Cross and Red Crescent Movement, Barzilai Medical Center, Trauma, Environment, EMS, UN, Organic, Pharmaceutical industry, Hospital, Health insurance, Nursing

A paramedic and Red Cross service that is a leader in mass-casualty response and EMS technology.

Key Points: 
  • A paramedic and Red Cross service that is a leader in mass-casualty response and EMS technology.
  • Barzilai Medical Center is the frontline hospital during times of conflict, providing critical medical care.
  • Kaplan Medical Center is a major general hospitals with a recognized center of excellence in trauma.
  • A UN-recognized humanitarian volunteer organization that provides rapid response to mass casualty disasters across the world.

International Fellowship of Christians and Jews Approves $5M in Emergency Humanitarian Aid for Distribution Throughout Israel Following Devastating Hamas Attacks

Retrieved on: 
Sunday, October 8, 2023
Food, Hezbollah, Sukkot, Hamas, Hope, Christians, Yom Kippur War, The Glory, French Hospital (La Providence), Ambulance, Barzilai Medical Center, NICU, Home Front Command, Medicine, Hospital, System, International Fellowship of Christians and Jews, Ministry, Ministry of Welfare, Poverty, FIDF, Jews, Yom Kippur, Shock, IDF, Atmosphere, Nightclub, Nursing, Drug, Iron, Fellow

JERUSALEM, Oct. 8, 2023 /PRNewswire/ -- In the hours following the massive and vicious attacks by Hamas terrorists on southern Israel in the early hours of Saturday morning October 7, the International Fellowship of Christians and Jews (The Fellowship) began planning its humanitarian aid response efforts as the IDF carries out Operation Swords of Iron, its retaliatory strikes in the Gaza Strip. More than 2,000 rockets were fired at Israel and hundreds of people were killed during the first day of conflict, with thousands more reported wounded and/or kidnapped. 

Key Points: 
  • Yael Eckstein, President and CEO of The Fellowship, said, "This is Israel's 9/11.
  • We still don't know everything that is going on or the extent, but we know it is unprecedented.
  • It raises disturbing memories of the Yom Kippur War, which started on almost this exact date 50 years ago.
  • "Right now, we are looking at what will happen in the north, as Hezbollah engages with artillery and rocket fire with Israel forces.

Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19

Retrieved on: 
Wednesday, August 2, 2023
Rebecca Sieff Hospital, Frontiers, University Medical Center, COVID-19, Inflammation, Immunotherapy, Patient, Barzilai Medical Center, Hadassah Medical Center, Viral, Acute respiratory distress syndrome, Mortality, ICU, Trial of the century, Paper, Chemokine, Phase, Therapy, Disease, Pharmaceutical industry, Data, Immunology

Nes-Ziona, Israel, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the peer-reviewed publication of clinical and exploratory data from a Phase Ib and a Phase IIa clinical trial in Frontiers in Immunology. The paper, entitled “Apoptotic cells for treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19” describes a multicenter study that was published in collaboration with researchers at Hadassah-Hebrew University Medical Center, Barzilai Medical Center and Ziv Medical Center Israel.

Key Points: 
  • The Phase I/II clinical trials evaluated the safety profile of Allocetra treatment as well as recovery from ARDS, intensive care unit (ICU) and hospital length-of-stay inflammatory parameters and cytokine/chemokine profile.
  • The mortality rate was compared to a matched control group hospitalized during the same period at Hadassah Medical Center.
  • All patients had elevated pro- and anti-inflammatory cytokines, chemokines, and additional immune modulators that steadily decreased following AllocetraTM treatment.
  • No serious related adverse events were reported with AllocetraTM treatment with an overall favorable safety profile.

International Fellowship of Christians and Jews Takes Action to Protect Civilians in Israel's South

Retrieved on: 
Thursday, May 11, 2023
French Hospital (La Providence), Hospital, Christians, Safety, Face, International Fellowship of Christians and Jews, Barzilai Medical Center, Jews, Fellow, Nursing

JERUSALEM, May 11, 2023 /PRNewswire/ -- In a quick response to the more than 500 rockets launched at southern Israel in the last two days, the International Fellowship of Christians and Jews (The Fellowship) announced the placement of five new bomb shelter units today in areas of Ashkelon identified by local authorities as lacking ample protection. The areas included residential spaces where homes still had no shelters as well as commercial zones where people had no refuge from incoming rockets. 

Key Points: 
  • The areas included residential spaces where homes still had no shelters as well as commercial zones where people had no refuge from incoming rockets.
  • The organization also purchased four protective vehicles that are used by local security officers to arrive quickly and safely at the scene of attacks.
  • The new shelters will provide much-needed protection to the residents of Ashkelon during these challenging times.
  • In recent years, The Fellowship has donated over 400 such shelters throughout the country, and has plans to renovate and equip 2,500 existing shelters.

FirstPoint Selected to Implement Private 5G Cellular Network with an Advanced IoT Connectivity Management Platform at a leading Israeli Hospital

Retrieved on: 
Wednesday, February 22, 2023
Organization, Internet of things, Barzilai Medical Center, Ministry of Communications and Information Technology (Egypt), Israel Innovation Authority, Innovation, MWC, SIM, Mobile phone

NETANYA, Israel, Feb. 22, 2023 /PRNewswire/ -- FirstPoint Mobile Guard, a leading provider of IoT connectivity management platforms, has been selected to run a pilot program aimed at setting up private 5G cellular networks at Barzilai Hospital, a leading hospital in Israel.

Key Points: 
  • NETANYA, Israel, Feb. 22, 2023 /PRNewswire/ -- FirstPoint Mobile Guard, a leading provider of IoT connectivity management platforms, has been selected to run a pilot program aimed at setting up private 5G cellular networks at Barzilai Hospital, a leading hospital in Israel.
  • FirstPoint  is a cutting-edge end-component (IoT) connectivity management platform that provides unparalleled control, flexibility, and cost-effectiveness to organizations deploying large networks of IoT devices.
  • FirstPoint's innovative technology simplifies the complex landscape of IoT management, enabling organizations to take control of their IoT ecosystems and reduce their connectivity costs by up to 75%.
  • "FirstPoint is excited to participate in this program and help advance the development of 5G technology in Israel.

EQS-News: Code Pharma BV: Antiviral drug Codivir shows promising effect against COVID-19

Retrieved on: 
Wednesday, September 1, 2021
Peptide, HIV-1, Human, Eleazar Sukenik, Life expectancy, Severe acute respiratory syndrome coronavirus 2, Infection, Coronavirus, Research, RNA, Orthornavirae, R, Hebrew University of Jerusalem, CASA, Clinical trial, Paulo, Safety, Barzilai Medical Center, Patient, Hadassah Medical Center, COVID-19, Virology, Department, Pharma, Pharmaceutical industry, Fine chemical, Vaccine

Code Pharma, a Dutch pharmaceutical company, is developing a direct antiviral drug against COVID-19.

Key Points: 
  • Code Pharma, a Dutch pharmaceutical company, is developing a direct antiviral drug against COVID-19.
  • Code Pharma discovered that the peptide had a direct antiviral effect against SARS-CoV-2, the novel Coronavirus causing COVID-19.
  • Due to its direct anti-viral effect, Codivir may have a similar beneficial effect on other RNA viruses, such as influenza.
  • Further information can be found at: https://www.codepharma.com/
    If you have any questions regarding Code Pharma, please contact us at: